Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flibanserin Safety Study in Women With HSDD
NCT00441558Phase 3Terminated
- Sponsor
- Sprout Pharmaceuticals
- Start
- Feb 2007
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of flibanserin in hypoactive sexual desire disorder (HSDD), sponsored by Sprout Pharmaceuticals. Primary endpoint: Frequency of Adverse Events at 52 weeks. Started Feb 2007; status: terminated.
02
Drugs
flibanserin
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT00441558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00441558.